Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 6/2016

12.10.2016 | Acute Myeloid Leukemias (H Erba, Section Editor)

Antibody-Based Treatment of Acute Myeloid Leukemia

verfasst von: Phillip M. Garfin, Eric J. Feldman

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.
Literatur
2.
Zurück zum Zitat Maloney DG et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188–95.PubMed Maloney DG et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188–95.PubMed
3.
Zurück zum Zitat Topp MS et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.CrossRefPubMed Topp MS et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.CrossRefPubMed
4.
5.
Zurück zum Zitat Jurcic JG. What happened to anti-CD33 therapy for acute myeloid leukemia? Curr Hematol Malig Rep. 2012;7(1):65–73.CrossRefPubMed Jurcic JG. What happened to anti-CD33 therapy for acute myeloid leukemia? Curr Hematol Malig Rep. 2012;7(1):65–73.CrossRefPubMed
6.
Zurück zum Zitat Weir EG, Borowitz MJ. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol. 2001;38(2):124–38.CrossRefPubMed Weir EG, Borowitz MJ. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol. 2001;38(2):124–38.CrossRefPubMed
8.
Zurück zum Zitat Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.CrossRefPubMed Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.CrossRefPubMed
9.
Zurück zum Zitat Jilani I et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118(4):560–6.CrossRefPubMed Jilani I et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118(4):560–6.CrossRefPubMed
10.
Zurück zum Zitat Ginaldi L et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22(2):185–91.CrossRefPubMed Ginaldi L et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22(2):185–91.CrossRefPubMed
11.
Zurück zum Zitat Golay J et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98(12):3383–9.CrossRefPubMed Golay J et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98(12):3383–9.CrossRefPubMed
13.
Zurück zum Zitat Feldman E et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 2003;17(2):314–8.CrossRefPubMed Feldman E et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia. 2003;17(2):314–8.CrossRefPubMed
14.
Zurück zum Zitat Jurcic JG et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res. 2000;6(2):372–80.PubMed Jurcic JG et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res. 2000;6(2):372–80.PubMed
15.
Zurück zum Zitat Sekeres MA et al. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013;98(1):119–28.CrossRefPubMedPubMedCentral Sekeres MA et al. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013;98(1):119–28.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125(22):3393–400.CrossRefPubMed Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125(22):3393–400.CrossRefPubMed
17.
Zurück zum Zitat Buyse M et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011;117(26):7007–13.CrossRefPubMedPubMedCentral Buyse M et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 2011;117(26):7007–13.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Takami A et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014;20(11):1785–90.CrossRefPubMed Takami A et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014;20(11):1785–90.CrossRefPubMed
19.
Zurück zum Zitat Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol. 2001;13(6):522–7.CrossRefPubMed Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol. 2001;13(6):522–7.CrossRefPubMed
20.
Zurück zum Zitat Sievers EL et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54.PubMed Sievers EL et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54.PubMed
21.
Zurück zum Zitat Larson RA et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–52.CrossRefPubMed Larson RA et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–52.CrossRefPubMed
22.
Zurück zum Zitat Hills RK et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–96.CrossRefPubMedPubMedCentral Hills RK et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–96.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Petersdorf SH et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.CrossRefPubMedPubMedCentral Petersdorf SH et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Kharfan-Dabaja MA et al. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013;163(3):315–25.CrossRefPubMed Kharfan-Dabaja MA et al. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013;163(3):315–25.CrossRefPubMed
25.
Zurück zum Zitat Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838–41.CrossRefPubMed Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838–41.CrossRefPubMed
26.
Zurück zum Zitat Castaigne S et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–16.CrossRefPubMed Castaigne S et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–16.CrossRefPubMed
27.
Zurück zum Zitat Sievers EL et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678–84.PubMed Sievers EL et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93(11):3678–84.PubMed
28.
Zurück zum Zitat Giles FJ et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.CrossRefPubMed Giles FJ et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.CrossRefPubMed
29.
Zurück zum Zitat Wadleigh M et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578–82.CrossRefPubMed Wadleigh M et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578–82.CrossRefPubMed
30.
Zurück zum Zitat Cohen AD et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant. 2002;30(1):23–8.CrossRefPubMed Cohen AD et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant. 2002;30(1):23–8.CrossRefPubMed
31.
Zurück zum Zitat McKoy JM et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604.CrossRefPubMed McKoy JM et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604.CrossRefPubMed
32.
Zurück zum Zitat Rajvanshi P et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310–4.CrossRefPubMed Rajvanshi P et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310–4.CrossRefPubMed
33.
Zurück zum Zitat Amadori S et al. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016;34(9):972–9.CrossRefPubMed Amadori S et al. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016;34(9):972–9.CrossRefPubMed
34.
Zurück zum Zitat McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma. 2002;2 Suppl 1:S35–9.CrossRefPubMed McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma. 2002;2 Suppl 1:S35–9.CrossRefPubMed
35.
Zurück zum Zitat Kantarjian HM et al., Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016. Kantarjian HM et al., Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016.
36.
Zurück zum Zitat Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother. 2013;62(2):217–23.CrossRefPubMed Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother. 2013;62(2):217–23.CrossRefPubMed
37.
Zurück zum Zitat Bross PF et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–6.PubMed Bross PF et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–6.PubMed
38.
Zurück zum Zitat Roboz GJ et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma. 2002;43(10):1951–5.CrossRefPubMed Roboz GJ et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma. 2002;43(10):1951–5.CrossRefPubMed
39.
Zurück zum Zitat Hollander I, Kunz A, Hamann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem. 2008;19(1):358–61.CrossRefPubMed Hollander I, Kunz A, Hamann PR. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem. 2008;19(1):358–61.CrossRefPubMed
40.
Zurück zum Zitat Jedema I et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia. 2004;18(2):316–25.CrossRefPubMed Jedema I et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia. 2004;18(2):316–25.CrossRefPubMed
41.
Zurück zum Zitat Cianfriglia M et al. Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. Int J Oncol. 2010;36(6):1513–20.CrossRefPubMed Cianfriglia M et al. Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. Int J Oncol. 2010;36(6):1513–20.CrossRefPubMed
42.
Zurück zum Zitat Kung Sutherland MS et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455–63.CrossRefPubMed Kung Sutherland MS et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455–63.CrossRefPubMed
43.
Zurück zum Zitat Fathi AT et al. SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML. in American Society for Hematology. 2015. Orland, Florida. Fathi AT et al. SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML. in American Society for Hematology. 2015. Orland, Florida.
44.
Zurück zum Zitat Stein AS et al. A phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood Cancer J. 2015;126(23):1. Stein AS et al. A phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood Cancer J. 2015;126(23):1.
45.
46.
Zurück zum Zitat Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma. 2003;44 Suppl 4:S37–47.CrossRefPubMed Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma. 2003;44 Suppl 4:S37–47.CrossRefPubMed
47.
Zurück zum Zitat Burke JM et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32(6):549–56.CrossRefPubMed Burke JM et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32(6):549–56.CrossRefPubMed
48.
Zurück zum Zitat Ringhoffer M et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol. 2005;130(4):604–13.CrossRefPubMed Ringhoffer M et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol. 2005;130(4):604–13.CrossRefPubMed
49.
Zurück zum Zitat Pagel JM et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107(5):2184–91.CrossRefPubMedPubMedCentral Pagel JM et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107(5):2184–91.CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Kantarjian HM et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016;122(14):2178–85.CrossRefPubMed Kantarjian HM et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016;122(14):2178–85.CrossRefPubMed
51.
Zurück zum Zitat Laszlo GS et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4):554–61.CrossRefPubMedPubMedCentral Laszlo GS et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4):554–61.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Friedrich M et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014;13(6):1549–57.CrossRefPubMed Friedrich M et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014;13(6):1549–57.CrossRefPubMed
53.
Zurück zum Zitat Teachey DT et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–7.CrossRefPubMedPubMedCentral Teachey DT et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–7.CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Kochenderfer JN et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–20.CrossRefPubMedPubMedCentral Kochenderfer JN et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–20.CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Walter RB et al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105(3):1295–302.CrossRefPubMed Walter RB et al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105(3):1295–302.CrossRefPubMed
56.
Zurück zum Zitat Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19(2):176–82.CrossRefPubMed Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19(2):176–82.CrossRefPubMed
57.
Zurück zum Zitat Chevallier P et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol. 2008;26(32):5192–7.CrossRefPubMed Chevallier P et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol. 2008;26(32):5192–7.CrossRefPubMed
58.
Zurück zum Zitat Olombel G et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127(17):2157–60.CrossRefPubMed Olombel G et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127(17):2157–60.CrossRefPubMed
59.
Zurück zum Zitat Pollard JA et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012;119(16):3705–11.CrossRefPubMedPubMedCentral Pollard JA et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012;119(16):3705–11.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Mortland L et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19(6):1620–7.CrossRefPubMedPubMedCentral Mortland L et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19(6):1620–7.CrossRefPubMedPubMedCentral
61.
Zurück zum Zitat Laszlo GS et al. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget. 2016. Laszlo GS et al. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget. 2016.
62.
Zurück zum Zitat Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control. 2004;11(2):97–104.PubMed Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control. 2004;11(2):97–104.PubMed
63.
Zurück zum Zitat Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–7.CrossRefPubMed Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–7.CrossRefPubMed
64.
65.
66.
Zurück zum Zitat Testa U et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100(8):2980–8.CrossRefPubMed Testa U et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100(8):2980–8.CrossRefPubMed
67.
Zurück zum Zitat Jordan CT et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–84.CrossRefPubMed Jordan CT et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–84.CrossRefPubMed
68.
Zurück zum Zitat Vergez F et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96(12):1792–8.CrossRefPubMedPubMedCentral Vergez F et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96(12):1792–8.CrossRefPubMedPubMedCentral
69.
Zurück zum Zitat Pelosi E, Castelli G, Testa U. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Blood Cells Mol Dis. 2015;55(4):336–46.CrossRefPubMed Pelosi E, Castelli G, Testa U. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Blood Cells Mol Dis. 2015;55(4):336–46.CrossRefPubMed
70.
Zurück zum Zitat Busfield SJ et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014;28(11):2213–21.CrossRefPubMed Busfield SJ et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014;28(11):2213–21.CrossRefPubMed
71.
Zurück zum Zitat Jin L et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5(1):31–42.CrossRefPubMed Jin L et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5(1):31–42.CrossRefPubMed
72.
Zurück zum Zitat Smith BD et al. First-in Man, Phase 1 Study of CSL362 (Anti-IL3Ralpha/Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse, in American Society of Hematology. 2014, American Society of Hematology: San Francisco, CA. p. 120. Smith BD et al. First-in Man, Phase 1 Study of CSL362 (Anti-IL3Ralpha/Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse, in American Society of Hematology. 2014, American Society of Hematology: San Francisco, CA. p. 120.
73.
Zurück zum Zitat Kung Sutherland MS et al. SGN-CD123A, a Pyrrolobenzodiazepine Dimer linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective ANti-Leukemic Activity in Multiple Preclinical Models of AML. Blood. 2015;126:330. Kung Sutherland MS et al. SGN-CD123A, a Pyrrolobenzodiazepine Dimer linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective ANti-Leukemic Activity in Multiple Preclinical Models of AML. Blood. 2015;126:330.
74.
Zurück zum Zitat Kovtun Y et al. ANnovel antibody drug conjugate of a CD123-targeting antibody with a potent DNA-Alkylator is highly active in preclinical models of AML with poor prognosis. EHA Learning Center. 2016: p. 135339. Kovtun Y et al. ANnovel antibody drug conjugate of a CD123-targeting antibody with a potent DNA-Alkylator is highly active in preclinical models of AML with poor prognosis. EHA Learning Center. 2016: p. 135339.
75.
Zurück zum Zitat Ritchey J et al. Targeting CD123 in Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecults (DARTs(R)). Blood Cancer J. 2013;122:360. Ritchey J et al. Targeting CD123 in Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecults (DARTs(R)). Blood Cancer J. 2013;122:360.
76.
Zurück zum Zitat Bakker AB et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64(22):8443–50.CrossRefPubMed Bakker AB et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64(22):8443–50.CrossRefPubMed
77.
Zurück zum Zitat Lu H et al. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew Chem Int Ed Engl. 2014;53(37):9841–5.CrossRefPubMedPubMedCentral Lu H et al. Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew Chem Int Ed Engl. 2014;53(37):9841–5.CrossRefPubMedPubMedCentral
78.
79.
Zurück zum Zitat Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets. 2015;19(1):37–54.CrossRefPubMed Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets. 2015;19(1):37–54.CrossRefPubMed
Metadaten
Titel
Antibody-Based Treatment of Acute Myeloid Leukemia
verfasst von
Phillip M. Garfin
Eric J. Feldman
Publikationsdatum
12.10.2016
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 6/2016
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-016-0349-7

Weitere Artikel der Ausgabe 6/2016

Current Hematologic Malignancy Reports 6/2016 Zur Ausgabe

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer

Myelodysplastic Syndromes (D Steensma, Section Editor)

Improving Prognostic Modeling in Myelodysplastic Syndromes

T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)

T-cell Lymphoma Epidemiology: the Known and Unknown

T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)

Sézary Syndrome: Clinical and Biological Aspects

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.